Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
scott gottlieb
10
×
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
fda
indiana blog main
indiana top stories
drug prices
glaxosmithkline
celgene
clinical study
donald trump
gene editing
ipo
medicare
venture capital
amgen
bristol-myers squibb
What
roundup
bio
drugs
awaited
cancer
celgene
costly
crispr
health
house
long
medications
medicine
notes
plan
rises
trump
unveiled
white
abbvie’s
according
administration
afternoon
ahead
airport
akcea
allogene
annual
anticipated
apocalypse
appetite
asco
barbecuing
beds
big
biopharma
biotech
black
blueprint
bosley's
Language
unset
unknown
Current search:
" scott gottlieb "
×
@xconomy.com
4 years ago
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
@xconomy.com
4 years ago
Bio Roundup: Cholesterol Check, J&J’s Opioid Hit, AbbVie’s Flop & More
@xconomy.com
4 years ago
White House Floats Canadian Import Plan But Excludes Many Costly Drugs
@xconomy.com
4 years ago
Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More
@xconomy.com
5 years ago
Notes from the JPM19 Vortex: Price Apocalypse, Celgene Fallout & More
@xconomy.com
5 years ago
Bio Roundup: $74B for Celgene, Two CAR-T Tales, Ready for SF & More
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More
@xconomy.com
5 years ago
Trump Pledges Lower Drug Prices, But Blueprint Is Short on Details